Skip to main content

Table 1 Patient characteristics

From: Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer

   Patients (N = 228)
Age (y/o) (Median = 69)  
  Age ≤ 60 11.0%
  60 < Ages ≤ 70 45.6%
  Age > 70 43.4%
Race   
  White 58.8%
  Black 35.5%
  Other 5.7%
Partner status   
  Yes 75.40%
  No 24.60%
Employment status   
  Yes 47.40%
  No 52.60%
Median pre-treatment PSA (ng/mL)   6.1 (1.3-32.5) ng/dL
Median pre-treatment Testosterone (nmol/L)   11 (3.99-39.87) nmol/L
Risk groups (D’Amico’s)   
  Low risk 38.6%
  Intermediate risk 55.3%
  High risk 6.1%
Sexual aid   
  None 61.9%
  Yes (Any) 38.1%
SBRT dose   
  36.25 Gy 84.2%
  35 Gy 13.2%
  Other 2.6%